Joseph G. Rogers, medico

Il Direttore del Texas Heart Institute del Baylor College of Medicine, Joseph G. Rogers, MD, è un cardiologo e Professore a Contratto presso la Divisione di Cardiologia della Duke University. È un leader di pensiero riconosciuto a livello internazionale e ampiamente pubblicato nel campo dell'insufficienza cardiaca, del trapianto cardiaco e della circolazione meccanicamente assistita.

Mostra biografia completa

Il dottor Rogers è appassionato di iniziative di assistenza basate sul valore, di fornitura e implementazione della gestione dell'assistenza e di strategie di salute della popolazione. La ricerca del dottor Rogers si concentra sugli aspetti clinici dell'insufficienza cardiaca avanzata, compresi i trattamenti farmacologici ed elettrici per l'insufficienza cardiaca sistolica, l'uso di dispositivi di supporto circolatorio meccanico, il trapianto cardiaco e le cure palliative.

Prima di entrare a far parte del Texas Heart Institute in qualità di Presidente e CEO, ha ricoperto il ruolo di Chief Medical Officer presso la Duke University Health System (DUHS) a Durham, nella Carolina del Nord, dove era responsabile di fornire una direzione clinica e strategica per le attività dei medici in tutte le sue entità cliniche. .

Il dottor Rogers ha conseguito la laurea in medicina presso il College of Medicine dell'Università del Nebraska a Omaha. Ha completato la sua formazione in medicina interna presso l'Università del Nebraska e la sua borsa di studio in cardiologia presso la Washington University di St. Louis, Missouri. È entrato a far parte della facoltà della Duke nel 2004 e ha ricoperto diversi ruoli di leadership, tra cui Direttore medico associato per la crescita e l'implementazione strategica, presidente ad interim del Dipartimento di Medicina della scuola e membro del consiglio di amministrazione di Duke Connected Care, il sistema sanitario Organizzazione assistenziale responsabile. Ha anche ricoperto il ruolo di collegamento chiave del sistema sanitario strategico con la Private Diagnostic Clinic, l'organizzazione di studi medici per i fornitori di Duke, dove ha sostenuto le innovazioni in termini di sicurezza e qualità in tutto il sistema sanitario.

Joseph G. Rogers, medico
Direttore, Texas Heart Institute presso il Baylor College of Medicine
Sedia dotata di O'Quinn/Willerson
Il Texas Heart Institute
6770 Bertner Avenue, MC 3-116
Houston, TX 77030
Ufficio: 832-355-9320 | Fax: 832-355-6810
E-mail: jrogers@texasheart.org

Vedi Pubblicazioni

Posizioni del Texas Heart Institute

Interessi

  • Insufficienza cardiaca avanzata
  • Trattamenti farmacologici ed elettrici investigativi per l'insufficienza cardiaca sistolica
  • Dispositivi di supporto circolatorio meccanico
  • Trapianto cardiaco
  • Cure palliative nel trattamento dello scompenso cardiaco

Formazione

  • Scuola di Medicina:

    Università del Nebraska (Omaha)

  • residenza

    Università del Nebraska (Omaha)

  • Borse di studio:

    Borsa di studio sulle malattie cardiovascolari, Washington University (St. Louis, Missouri)

Affiliazioni accademiche e cliniche

Riconoscimenti, premi e abbonamenti

Pubblicazioni

4862227 7DBQSZ99 1 alternative alla sperimentazione animale 10 quando disc Rogers 37270 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NEEKYH88%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raghuram%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRaghuram%2C%20A.%2C%20Sprung%2C%20K.%2C%20Coulter%2C%20S.%20et%20al.%20%282025%29.%20Shaping%20the%20Future%20of%20%26%23x201C%3BCardio-Kidney-Metabolic%26%23x201D%3B%20Health%3A%20Insights%20From%20The%20Texas%20Heart%20Institute%26%23x2019%3Bs%202024%20Cardiometabolic%20Syndrome%20Conference.%20%26lt%3Bi%26gt%3BTexas%20Heart%20Institute%20Journal%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B52%26lt%3B%5C%2Fi%26gt%3B%2C%20e248536.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8536%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8536%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Shaping%20the%20Future%20of%20%5Cu201cCardio-Kidney-Metabolic%5Cu201d%20Health%3A%20Insights%20From%20The%20Texas%20Heart%20Institute%27s%202024%20Cardiometabolic%20Syndrome%20Conference%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arjun%22%2C%22lastName%22%3A%22Raghuram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Sprung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20At%20the%20Texas%20Heart%20Institute%26%23039%3Bs%202024%20Cardiometabolic%20Syndrome%20Conference%2C%20held%20on%20August%2023%2C%202024%2C%20experts%20from%20diverse%20academic%20fields%20spoke%20about%20novel%20initiatives%20for%20addressing%20the%20worsening%20projections%20for%20cardiometabolic%20syndrome.%20Four%20major%20areas%20in%20which%20innovation%20is%20ongoing%20were%20highlighted%3A%20technology%2C%20policy%2C%20population%20health%2C%20and%20lifestyle%20and%20behavioral%20modification.%20This%20article%20presents%20a%20brief%20contextualization%2C%20summary%2C%20and%20analysis%20of%20the%20novel%20initiatives%20being%20implemented%20in%20each%20of%20these%204%20areas%20to%20address%20cardiometabolic%20syndrome.%20Despite%20alarming%20projections%2C%20cardiometabolic%20syndrome%20presents%20a%20unique%20opportunity%20for%20innovators%20to%20drive%20change%20through%20collaborative%2C%20multidisciplinary%20efforts.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-24-8536%22%2C%22ISSN%22%3A%221526-6702%2C%200730-2347%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fthij.kglmeridian.com%5C%2Fview%5C%2Fjournals%5C%2Fthij%5C%2F52%5C%2F1%5C%2Farticle-e248536.xml%22%2C%22collections%22%3A%5B%227DBQSZ99%22%5D%2C%22dateModified%22%3A%222025-02-06T23%3A08%3A48Z%22%7D%7D%2C%7B%22key%22%3A%229X227XLK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussain%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHussain%2C%20A.%2C%20Ramsey%2C%20D.%2C%20Lee%2C%20M.%20et%20al.%20%282023%29.%20Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900185%26%23x2013%3B3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliza%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ramsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhruv%22%2C%22lastName%22%3A%22Mahtta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Nambi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20A.%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%20D.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waleed%20T.%22%2C%22lastName%22%3A%22Kayani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javed%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leandro%22%2C%22lastName%22%3A%22Slipczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Biykem%22%2C%22lastName%22%3A%22Bozkurt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sankar%20D.%22%2C%22lastName%22%3A%22Navaneethan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Multiple%20clinical%20trials%20have%20demonstrated%20significant%20cardiovascular%20benefit%20with%20use%20of%20sodium-glucose%20cotransporter-2%20%28SGLT2%29%20inhibitors%20in%20patients%20with%20type%202%20diabetes%20%28T2DM%29%20and%20heart%20failure%20%28HF%29%20irrespective%20of%20ejection%20fraction.%20There%20are%20limited%20data%20evaluating%20real-world%20prescription%20and%20practice%20patterns%20of%20SGLT2%20inhibitors.%5CnOBJECTIVES%3A%20The%20authors%20sought%20to%20assess%20utilization%20rates%20and%20facility-level%20variation%20in%20the%20use%20among%20patients%20with%20established%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%2C%20HF%2C%20and%20T2DM%20using%20data%20from%20the%20nationwide%20Veterans%20Affairs%20health%20care%20system.%5CnMETHODS%3A%20The%20authors%20included%20patients%20with%20established%20ASCVD%2C%20HF%2C%20and%20T2DM%20seen%20by%20a%20primary%20care%20provider%20between%20January%201%2C%202020%2C%20and%20December%2031%2C%202020.%20They%20assessed%20the%20use%20of%20SGLT2%20inhibitors%20and%20the%20facility-level%20variation%20in%20their%20use.%20Facility-level%20variation%20was%20computed%20using%20median%20rate%20ratios%2C%20a%20measure%20of%20likelihood%20that%202%5Cu00a0random%20facilities%20differ%20in%20use%20of%20SGLT2%20inhibitors.%5CnRESULTS%3A%20Among%20105%2C799%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20across%20130%20Veterans%20Affairs%20facilities%2C%2014.6%25%20received%20SGLT2%20inhibitors.%20Patients%20receiving%20SGLT2%20inhibitors%20were%20younger%20men%20with%20higher%20hemoglobin%20A1c%20and%20estimated%20glomerular%20filtration%20rate%20and%20were%20more%20likely%20to%20have%20HF%20with%20reduced%20ejection%20fraction%20and%20ischemic%20heart%20disease.%20There%20was%20significant%20facility-level%20variation%20of%20SGLT2%20inhibitor%20use%2C%20with%20an%20adjusted%20median%20rate%20ratio%20of%201.55%20%2895%25%5Cu00a0CI%3A%201.46-1.64%29%2C%20indicating%20a%2055%25%20residual%20difference%20in%20SGLT2%20inhibitor%20use%20among%20similar%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20receiving%20care%20at%202%20random%20facilities.%5CnCONCLUSIONS%3A%20Utilization%20rates%20of%20SGLT2%20inhibitors%20are%20low%20in%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%2C%20with%20high%20residual%20facility-level%20variation.%20These%20findings%20suggest%20opportunities%20to%20optimize%20SGLT2%20inhibitor%20use%20to%20prevent%20future%20adverse%20cardiovascular%20events.%22%2C%22date%22%3A%222023-05-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.03.024%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%227DBQSZ99%22%2C%22GL8QP2FN%22%2C%22FCV4W3RS%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T18%3A07%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22ZANSTJ68%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitra%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaitra%2C%20N.%20S.%2C%20Dugger%2C%20S.%20J.%2C%20Balachandran%2C%20I.%20C.%20et%20al.%20%282023%29.%20Impact%20of%20the%202018%20UNOS%20heart%20transplant%20policy%20changes%20on%20patient%26%23xA0%3Boutcomes.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900038%26%23x2013%3B0.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.01.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.01.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%202018%20UNOS%20heart%20transplant%20policy%20changes%20on%20patient%5Cu00a0outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20S.%22%2C%22lastName%22%3A%22Maitra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20J.%22%2C%22lastName%22%3A%22Dugger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%20C.%22%2C%22lastName%22%3A%22Balachandran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prateeti%22%2C%22lastName%22%3A%22Khazanie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22In%202018%2C%20the%20United%20Network%20for%20Organ%20Sharing%20implemented%20a%206-tier%20allocation%20policy%20to%20replace%20the%20prior%203-tier%20system.%20Given%20increasing%20listings%20of%20critically%20ill%20candidates%20for%20heart%20transplantation%20and%20lengthening%20waitlist%20times%2C%20the%20new%20policy%20aimed%20to%20better%20stratify%20candidates%20by%20waitlist%20mortality%2C%20shorten%20waiting%20times%20for%20high%20priority%20candidates%2C%20add%20objective%20criteria%20for%20common%20cardiac%20conditions%2C%20and%20further%20broaden%20sharing%20of%20donor%20hearts.%20There%20have%20been%20significant%20shifts%20in%20cardiac%20transplantation%20practices%20and%20patient%20outcomes%20following%20the%20implementation%20of%20the%20new%5Cu00a0policy%2C%20including%20changes%20in%20listing%20practices%2C%20waitlist%20time%20and%20mortality%2C%20transplant%20donor%20characteristics%2C%20post-transplantation%20outcomes%2C%20and%20mechanical%20circulatory%20support%20use.%20This%20review%20aims%20to%20highlight%20emerging%20trends%20in%20United%20States%20heart%20transplantation%20practice%20and%20outcomes%20following%20the%20implementation%20of%20the%202018%20United%20Network%20for%20Organ%20Sharing%20heart%20allocation%20policy%20and%20to%20address%20areas%20for%20future%20modification.%22%2C%22date%22%3A%22Feb%2016%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.01.009%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%224XZV96J9%22%2C%227DBQSZ99%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A35%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22UEPATAH5%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Civitello%20and%20Rogers%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCivitello%2C%20A.%20B.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282023%29.%20Toward%20a%20self-actuating%20continuous%20flow%20ventricular%20assist%20device%3A%20the%20pudding%20is%20in%20the%20proof.%20%26lt%3Bi%26gt%3BASAIO%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B69%26lt%3B%5C%2Fi%26gt%3B%2C%2059%26%23x2013%3B60.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001881%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001881%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Toward%20a%20self-actuating%20continuous%20flow%20ventricular%20assist%20device%3A%20the%20pudding%20is%20in%20the%20proof%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jan%2001%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FMAT.0000000000001881%22%2C%22ISSN%22%3A%221538-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22TXW6RMW4%22%5D%2C%22dateModified%22%3A%222023-01-06T17%3A15%3A59Z%22%7D%7D%2C%7B%22key%22%3A%2282UUHA72%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wang%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWang%2C%20N.%2C%20Gray%2C%20Z.%2C%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20et%20al.%20%282023%29.%20Robot-assisted%20resection%20of%20tricuspid%20valve%20papillary%20fibroelastoma.%20%26lt%3Bi%26gt%3BAnnals%20of%20Thoracic%20Surgery%20Short%20Reports%26lt%3B%5C%2Fi%26gt%3B%2C%20S2772993123001791.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.atssr.2023.04.007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.atssr.2023.04.007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Robot-assisted%20resection%20of%20tricuspid%20valve%20papillary%20fibroelastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%22%2C%22lastName%22%3A%22Gray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20K.%22%2C%22lastName%22%3A%22Liao%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%225%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.atssr.2023.04.007%22%2C%22ISSN%22%3A%2227729931%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2772993123001791%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%22C2VFJYPK%22%2C%22Q46ISS7S%22%5D%2C%22dateModified%22%3A%222023-07-21T19%3A10%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22R3YNCLJK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Felker%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFelker%2C%20G.%20M.%2C%20Buttrick%2C%20P.%2C%20Rosenzweig%2C%20A.%20et%20al.%20%282022%29.%20Heart%20Failure%20Strategically%20Focused%20Research%20Network%3A%20Summary%20of%20results%20and%20future%20directions.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%20e025517.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.025517%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.025517%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Heart%20Failure%20Strategically%20Focused%20Research%20Network%3A%20Summary%20of%20results%20and%20future%20directions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Felker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Buttrick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Rosenzweig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Dale%22%2C%22lastName%22%3A%22Abel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larry%20A.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Bristow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saumya%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20D.%22%2C%22lastName%22%3A%22DeVore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavros%20G.%22%2C%22lastName%22%3A%22Drakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20C.%22%2C%22lastName%22%3A%22Fang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20E.%22%2C%22lastName%22%3A%22Freedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%20F.%22%2C%22lastName%22%3A%22Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dean%20Y.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20A.%22%2C%22lastName%22%3A%22McKinsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Newton-Cheh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravi%20V.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svati%20H.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Stehlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%20H.%22%2C%22lastName%22%3A%22Selzman%22%7D%5D%2C%22abstractNote%22%3A%22Heart%20failure%20remains%20among%20the%20most%20common%20and%20morbid%20health%20conditions.%20The%20Heart%20Failure%20Strategically%20Focused%20Research%20Network%20%28HF%20SFRN%29%20was%20funded%20by%20the%20American%20Heart%20Association%20to%20facilitate%20collaborative%2C%20high-impact%20research%20in%20the%20field%20of%20heart%20failure%20across%20the%20domains%20of%20basic%2C%20clinical%2C%20and%20population%20research.%20The%20Network%20was%20also%20charged%20with%20developing%20training%20opportunities%20for%20young%20investigators.%20Four%20centers%20were%20funded%20in%202016%3A%20Duke%20University%2C%20University%20of%20Colorado%2C%20University%20of%20Utah%2C%20and%20Massachusetts%20General%20Hospital-University%20of%20Massachusetts.%20This%20report%20summarizes%20the%20aims%20of%20each%20center%20and%20major%20research%20accomplishments%2C%20as%20well%20as%20training%20outcomes%20from%20the%20HF%20SFRN.%22%2C%22date%22%3A%22Sept%2020%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.025517%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%22C27MTI39%22%5D%2C%22dateModified%22%3A%222022-10-05T15%3A45%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22QNPYBRQJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Golden%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGolden%2C%20L.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Heart%20failure%20drug%20therapy%3A%20New%20treatments%2C%20new%20guidelines.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B49%26lt%3B%5C%2Fi%26gt%3B%2C%20e227920.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7920%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7920%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Heart%20failure%20drug%20therapy%3A%20New%20treatments%2C%20new%20guidelines%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Golden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Sept%2001%2C%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-22-7920%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227PRCM4JP%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22X2D36SJL%22%2C%22MDTREPAF%22%5D%2C%22dateModified%22%3A%222022-11-04T15%3A28%3A31Z%22%7D%7D%2C%7B%22key%22%3A%2289MC2836%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cogswell%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCogswell%2C%20R.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Residual%20heart%20failure%20on%20mechanically%20assisted%20circulation%3A%20A%20call%20to%20action.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20482%26%23x2013%3B484.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Residual%20heart%20failure%20on%20mechanically%20assisted%20circulation%3A%20A%20call%20to%20action%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Cogswell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22July%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2022.05.002%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A42%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22QTYXGFMP%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Al%20Rifai%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAl%20Rifai%2C%20M.%2C%20Newby%2C%20L.%20K.%2C%20Nair%2C%20A.%20P.%20et%20al.%20%282022%29.%20SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%20%26lt%3Bi%26gt%3BCurr%20Atheroscler%20Rep%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Al%20Rifai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20Kristin%22%2C%22lastName%22%3A%22Newby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arunima%22%2C%22lastName%22%3A%22Misra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Savitri%22%2C%22lastName%22%3A%22Fedson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20In%20this%20review%2C%20we%20discuss%20the%20mechanisms%20of%20action%20of%20sodium-glucose%20cotransporter-2%20inhibitors%20%28SGLT-2i%29%20and%20the%20purported%20protective%20effects%20for%20mitigating%20heart%20failure%20%28HF%29-related%20outcomes.%5CnRECENT%20FINDINGS%3A%20Major%20randomized%20clinical%20trials%20have%20demonstrated%20the%20cardiovascular%20safety%20and%20efficacy%20of%20SGLT-2i%20among%20patients%20without%20known%20HF%20and%20those%20with%20established%20HF%20with%20reduced%20ejection%20fraction%20or%20preserved%20ejection%20fraction%20%28HFrEF%20and%20HFpEF%20respectively%29.%20Recent%20HF%20guidelines%20have%20incorporated%20SGLT-2i%20in%20HF%20treatment%20algorithms.%20SGLT-2i%20have%20emerged%20as%20a%20novel%20treatment%20for%20both%20prevention%20of%20HF%20and%20reduction%20of%20cardiovascular%20morbidity%20and%20mortality%20among%20patients%20with%20existing%20HFrEF%20or%20HFpEF.%22%2C%22date%22%3A%22June%2002%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11883-022-01038-2%22%2C%22ISSN%22%3A%221534-6242%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22ZSY78DJL%22%5D%2C%22dateModified%22%3A%222022-07-06T19%3A09%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22Y6VPWZGE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shah%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BShah%2C%20P.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Thrivival%3A%20Thriving%20and%20surviving%20for%20left%20ventricular%20assist%20device%20patients.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20333%26%23x2013%3B335.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.02.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.02.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Thrivival%3A%20Thriving%20and%20surviving%20for%20left%20ventricular%20assist%20device%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Palak%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2022.02.009%22%2C%22ISSN%22%3A%2222131779%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2213177922001767%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%22ZH6PLEMG%22%5D%2C%22dateModified%22%3A%222022-05-12T13%3A34%3A19Z%22%7D%7D%5D%7D
Raghuram, A., Sprung, K., Coulter, S. et al. (2025). Modellare il futuro della salute "cardio-renale-metabolica": approfondimenti dalla conferenza sulla sindrome cardiometabolica del 2024 del Texas Heart Institute. Giornale del Texas Heart Institute 52, E248536. https://doi.org/10.14503/THIJ-24-8536.
Hussain, A., Ramsey, D., Lee, M. et al. (2023). Tassi di utilizzo degli inibitori SGLT2 tra i pazienti con diabete di tipo 2, insufficienza cardiaca e malattia cardiovascolare aterosclerotica: approfondimenti dal Department of Veterans Affairs. JACC Insufficienza cardiaca, S2213-1779(23)00185–3. https://doi.org/10.1016/j.jchf.2023.03.024.
Maitra, N. S., Dugger, S. J., Balachandran, I. C. et al. (2023). Impatto delle modifiche alla politica UNOS sui trapianti cardiaci del 2018 sugli esiti dei pazienti. JACC Insufficienza cardiaca, S2213-1779(23)00038–0. https://doi.org/10.1016/j.jchf.2023.01.009.
Civitello, A.B. e Rogers, JG (2023). Verso un dispositivo di assistenza ventricolare a flusso continuo autoazionante: il budino è nella prova. ASAIO J 6959-60. https://doi.org/10.1097/MAT.0000000000001881.
Wang, N., Gray, Z., Rogers, J.G. et al. (2023). Resezione robotizzata del fibroelastoma papillare della valvola tricuspide. Brevi relazioni sugli Annali di chirurgia toracica, S2772993123001791. https://doi.org/10.1016/j.atssr.2023.04.007.
Felker, G.M., Buttrick, P., Rosenzweig, A. et al. (2022). Rete di ricerca focalizzata strategicamente sull'insufficienza cardiaca: sintesi dei risultati e direzioni future. J Am Heart Assoc 11, E025517. https://doi.org/10.1161/JAHA.122.025517.
D'oro, L. e Rogers, JG (2022). Terapia farmacologica per lo scompenso cardiaco: nuovi trattamenti, nuove linee guida. Tex Heart Institute J 49, E227920. https://doi.org/10.14503/THIJ-22-7920.
Cogswell, R. e Rogers, JG (2022). Insufficienza cardiaca residua nella circolazione meccanicamente assistita: un invito all’azione. JACC Insufficienza cardiaca 10482-484. https://doi.org/10.1016/j.jchf.2022.05.002.
Al Rifai, M., Newby, L.K., Nair, A.P. et al. (2022). Inibitori SGLT-2 per pazienti con insufficienza cardiaca: cosa abbiamo imparato di recente? Curr Atheroscler Rep. https://doi.org/10.1007/s11883-022-01038-2.
Shah, P. e Rogers, JG (2022). Thrivival: prosperità e sopravvivenza per i pazienti con dispositivo di assistenza ventricolare sinistra. JACC Insufficienza cardiaca 10333-335. https://doi.org/10.1016/j.jchf.2022.02.009.

Notizie recenti

Vedi tutto

Leadership con competenza e compassione: la classe di giugno 2025 della Texas Heart Institute Perfusion School

La School of Perfusion Technology del Texas Heart Institute (THI) è orgogliosa di aggiungere otto nuovi talentuosi ex studenti agli oltre 1000...

Leggi di più

Presentazione del futuro della medicina cardiovascolare: il programma di borse di studio del Texas Heart Institute celebra i laureati in cardiologia del 2025

La sera del 6 giugno 2025, il Texas Heart Institute presso il Baylor College of Medicine (THI) ha celebrato i risultati...

Leggi di più
La tecnologia indossabile

Modellare il futuro della salute metabolica: approfondimenti dal Texas Heart Institute

Il 23 agosto 2024, il Texas Heart Institute ha ospitato la conferenza sulla sindrome cardiometabolica: una crisi sanitaria della popolazione, riunendo i principali...

Leggi di più
Frammenti di codice PHP Powered By: XYZScripts.com